Plain-English translation of NCT07293247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a newer type of radiation therapy called intensity-modulated radiation therapy (I²-PORT) for people who have had surgery for non-small cell lung cancer and still have cancer remaining in their lymph nodes after . Researchers want to know if adding this targeted radiation therapy after surgery helps people live longer without their cancer coming back, compared to standard treatment alone. The study will also carefully monitor whether this treatment causes any serious side effects affecting the heart or lungs.
Many people with advanced lung cancer still have cancer in their lymph nodes even after and surgery, which means their cancer is more likely to return. This trial exists to see if using newer, more precise radiation therapy can better target these remaining cancer cells and improve survival without causing unacceptable harm.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group receives standard or immunotherapy as usual. The other group receives targeted radiation therapy given 5 days a week for 5 to 6 weeks (starting 4 to 12 weeks after surgery), followed by standard or immunotherapy. Throughout the study, you will have regular imaging scans (CT, MRI, or PET), blood tests, and check-ins to monitor how you're doing and watch for any side effects. The study will follow you for several years to see how long you stay cancer-free.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States